Vertex Pharmaceuticals (VRTX)
$177.66
0.00 (0.00%)
VRTX Stock Quote Delayed 15 Minutes
Previous Close
$177.66
Market Cap
45.27B
PE Ratio
206.58
EPS
0.86
Volume (Avg. Vol.)
Day's Range
177.66 - 177.66
52-Week Range
145.37 - 195.81
Dividend & Yield
N/A (N/A)
VRTX Stock Predictions, Articles, and Vertex Pharmaceuticals News
3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics
Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.
3 Stocks to Watch on Thursday: Mondelez International Inc (MDLZ), Paypal Holdings Inc (PYPL) and Vertex Pharmaceuticals Incorporated (VRTX)
Mondelez (MDLZ) beat earnings expectations, Paypal (PYPL) revenue grew 24% and Vertex Pharmaceuticals' (VRTX) adjusted income up 74%.
Vertex Pharmaceuticals (VRTX) a Buy on Healthy Sales Growth
Currently, Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. This represents no change from the previous week and is the same ranking VRTX has had from Portfolio Grader for 4 months.
Vertex Pharmaceuticals’ (VRTX) Strong Quant Score Make it a Buy
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a member of the 350 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. The market value of VRTX is $35.6 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader score places it 32 among the 350 companies in this industry group, positioning it among the leaders; in the top quartile of the sector with a ranking of 102 among the 782 companies in the sector, and number 591 in the nearly 5,000 company Portfolio Grader universe.
Vertex Pharmaceuticals (VRTX) a Buy on Solid Sales Growth
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is ranked as a Buy using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking VRTX has had from Portfolio Grader for 4 months.
Vertex Pharmaceuticals’ (VRTX) Healthy Quant Score Make it a Buy
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 781 company GICS Health Care sector. VRTX's market value is $37.2 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for VRTX puts it 60 among the 349 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 158 among the 781 companies in the sector, and number 1,038 in the nearly 5,000 company Portfolio Grader universe.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
